Bioactive secretory leukocyte protease inhibitor (SLPI)-derived short peptides (SDSPs) attenuate LPS-induced inflammatory responses in macrophages.
SLPI-derived short peptides (SDSPs) are getting attention for their impact on inflammation research. A team from Chiang Mai University found these bioactive fragments can dial down the inflammatory response in macrophages exposed to lipopolysaccharide (LPS), a classic trigger for immune overdrive in the lab. That’s a big deal for anyone studying immune system regulation and the search for next-gen anti-inflammatory compounds.
Sci Rep
by Jarisarapurin W, Kunchana K, Srisopar O et al.
“Bioactive secretory leukocyte protease inhibitor (SLPI)-derived short peptides (SDSPs) attenuate LPS-induced inflammatory responses in macrophages. Jarisarapurin W(1)(2)(3), Kunchana K(1)(2), Srisopar O(1)(2), Bunsoong K(1)(2), Roytrakul S(4), Kumphune S(5)(6). Author information: (1)Biomedical Engineering Institute, CMU-BIOPOLIS building, Chiang Mai University- Mae, Hia campus, Mueang Chiang Mai District, Chiang Mai, 50100, Thailand. (2)Biomedical Engineering and Innovation Research Centre, CMU-BIOPOLIS building, Chiang Mai University, Mae Hia campus, Mueang Chiang Mai District, Chiang Mai, 50100, Thailand. (3)Office of Research Administration, Chiang Mai University, Chiang Mai University, Chiang Mai, 50200, Thailand. (4)Functional Proteomics Technology Laboratory, National Centre for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathumthani, 12120, Thailand. (5)Biomedical Engineering Institute, CMU-BIOPOLIS building, Chiang Mai University- Mae, Hia campus, Mueang Chiang Mai District, Chiang Mai, 50100, Thailand. sarawut.kumphune@cmu.ac.th. (6)Biomedical Engineering and Innovation Research Centre, CMU-BIOPOLIS building, Chiang Mai University, Mae Hia campus, Mueang Chiang Mai District, Chiang Mai, 50100, Thailand. sarawut.kumphune@cmu.ac.th. Conflict of interest statement: Declarations. Competing interests: The authors declare no competing interests. Ethics declarations. This article does not contain any studies with human or animal participants.”
Here’s what happened: Researchers isolated short peptides from secretory leukocyte protease inhibitor (SLPI), a natural protein with known immune functions. They exposed mouse macrophage cells to LPS—basically throwing a molecular wrench into the works to induce inflammation. Then they hit these cells with SDSPs. The result? A clear reduction in inflammatory markers, showing SDSPs can actively blunt the cellular freak-out triggered by LPS.
Why does this matter? Peptide-based approaches to modulating immune responses have huge potential. The study suggests short, targeted sequences can be just as effective as full-length proteins, maybe even with fewer side effects or less complexity.
Key takeaway:
Short peptides derived from SLPI can calm LPS-induced inflammation in macrophages
This supports the idea that precise peptide fragments can be valuable tools for immune research
The research didn’t involve animal or human testing—strictly in vitro cell work. That’s the norm for this early stage, but it’s a practical step toward bigger studies down the line.
For anyone building a peptide research portfolio, SDSPs offer a fresh angle on anti-inflammatory mechanisms. Want to dig deeper into peptide-based immune modulation? Check the peptide research index for more on immune-targeted compounds.
The field keeps getting more interesting. Peptides like SDSPs are worth watching as research compounds with clear potential.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.